Search and analyze individual stocks with comprehensive metrics

Astonea Labs Ltd

ASTONEALABPharmaceuticals
154.00+0.00 (+0.00%)
As on 19 Jan 2026, 10:09 amMarket Open

Fundamental Score

...

Astonea Labs Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Excellent

Return on Equity

44.66%
Excellent

Return on Capital Employed

19.74%

Operating Profit Margin (5Y)

N/A
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

33.98x

Market Capitalization

157.67 (Cr)

Industry P/E

31.77x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-33.33%
Excellent

YoY Quarterly Sales Growth

40.24%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Poor

Debt to Equity

0.73x
Good

Interest Coverage

2.93x

Free Cash Flow (5Y)

N/A

Ownership Structure

Good

Promoter Holding

72.30%
Poor

FII Holding

2.51%
Poor

DII Holding

0.35%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
72.30%
Promoter Holding
157.67 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of ASTONEALAB across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Return on Equity (44.66%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (19.74%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Revenue Growth (40.24%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Balanced Promoter Holding (72.30%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

5 factors identified

Profit Decline Concern (-33.33%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.

Limited Institutional Interest (FII+DII: 2.86%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Astonea Labs Ltd

About ASTONEALAB

Business Overview

Astonea Labs Limited manufactures and markets pharmaceutical and cosmetic products under the Glow Up, Avicel, and Regero brand names in India and internationally. It offers pharmaceutical products, including generics, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as cosmetic and personal care products such as skincare, haircare, anti-aging, ethical, and organic cosmetic lines. The company offers its products in tablets, capsules, softgels, soaps, oral and external powders, ointments, aerosols, creams, and lotions, as well as toothpastes and mouthwashes. Astonea Labs Limited was incorporated in 2017 and is based in Panchkula, India.

Company Details

Symbol:ASTONEALAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Ashish Gulati
MD & Director
Ms. Pooja Singh
Executive Director
Mr. Sumit Kumar
Chief Financial Officer

ASTONEALAB Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)44.66%
Return on Capital Employed19.74%
Operating Profit Margin (5Y)N/A%
Debt to Equity Ratio0.73
Interest Coverage Ratio2.93

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth-33.33%
YoY Quarterly Sales Growth40.24%

Frequently Asked Questions

What is the current price of Astonea Labs Ltd (ASTONEALAB)?

As of 19 Jan 2026, 10:09 am IST, Astonea Labs Ltd (ASTONEALAB) is currently trading at ₹154.00. The stock has a market capitalization of ₹157.67 (Cr).

Is ASTONEALAB share price Overvalued or Undervalued?

ASTONEALAB is currently trading at a P/E ratio of 33.98x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Astonea Labs Ltd share price?

Key factors influencing ASTONEALAB's price include its quarterly earnings growth (Sales Growth: 40.24%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Astonea Labs Ltd a good stock for long-term investment?

Astonea Labs Ltd shows a 5-year Profit Growth of N/A% and an ROE of 44.66%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.73 before investing.

How does Astonea Labs Ltd compare with its industry peers?

Astonea Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare ASTONEALAB's P/E of 33.98x and ROE of 44.66% against the industry averages to determine its competitive standing.

What is the P/E ratio of ASTONEALAB and what does it mean?

ASTONEALAB has a P/E ratio of 33.98x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹34 for every ₹1 of annual earnings.

How is ASTONEALAB performing according to Bull Run's analysis?

ASTONEALAB has a Bull Run fundamental score of 31.6/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does ASTONEALAB belong to?

ASTONEALAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Astonea Labs Ltd.

What is Return on Equity (ROE) and why is it important for ASTONEALAB?

ASTONEALAB has an ROE of 44.66%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Astonea Labs Ltd generates profits from shareholders' equity.

How is ASTONEALAB's debt-to-equity ratio and what does it indicate?

ASTONEALAB has a debt-to-equity ratio of 0.73, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.

What is ASTONEALAB's dividend yield and is it a good dividend stock?

ASTONEALAB offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has ASTONEALAB grown over the past 5 years?

ASTONEALAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in ASTONEALAB and why does it matter?

Promoters hold 72.30% of ASTONEALAB shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is ASTONEALAB's market capitalization category?

ASTONEALAB has a market capitalization of ₹158 crores, placing it in the Small-cap category.

How volatile is ASTONEALAB stock?

ASTONEALAB has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for ASTONEALAB?

ASTONEALAB has a 52-week high of ₹N/A and low of ₹N/A.

What is ASTONEALAB's operating profit margin trend?

ASTONEALAB has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.

How is ASTONEALAB's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 40.24% and YoY Profit Growth of -33.33%.

What is the institutional holding pattern in ASTONEALAB?

ASTONEALAB has FII holding of 2.51% and DII holding of 0.35%. Significant institutional holding often suggests professional confidence in the stock.